• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Consumers

  • Print
  • Share
  • E-mail

Perinatal Guidelines Update

The "Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States" have been revised to include:

Updates to Clinical Scenario #3. The new information discusses a 3 to 7 day "tail" of postpartum maternal ZDV/3TC following single dose maternal/infant nevirapine; this "tail" may reduce the risk of nevirapine resistance.

Updated information on the role of cesarean delivery in preventing mother-to-child transmission of HIV.
An updated Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy, including a new section on tipranavir.
A Perinatal Antiretroviral Guidelines Working Group Conflict of Interest Disclosure (Appendix).

Updated information appears highlighted in yellow.

You can download the updated guidelines, or request to receive them by e-mail or hard copy from the AIDSinfo Web site: www.aidsinfo.nih.gov.

The AIDSinfo website is also a useful source of other information related to HIV/AIDS, including other treatment and prevention guidelines, downloadable databases for PDAs (Personal Digital Assistants), fact sheets, and HIV/AIDS-related clinical trials information.

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration